PMID- 34792111
OWN - NLM
STAT- MEDLINE
DCOM- 20220718
LR  - 20221029
IS  - 1532-2092 (Electronic)
IS  - 1099-5129 (Print)
IS  - 1099-5129 (Linking)
VI  - 24
IP  - 6
DP  - 2022 Jul 15
TI  - International cohort study on the effectiveness of dronedarone and other 
      antiarrhythmic drugs for atrial fibrillation in real-world practice (EFFECT-AF).
PG  - 899-909
LID - 10.1093/europace/euab262 [doi]
AB  - AIMS: To evaluate the effectiveness and safety of dronedarone compared with other 
      commonly used antiarrhythmic drugs (AADs) for preventing atrial fibrillation (AF) 
      recurrences. METHODS AND RESULTS: An international observational cohort study in 
      Germany, Spain, Italy, and the USA enrolling patients with AF receiving AAD 
      therapy. Patients with New York Heart Association (NYHA) Class IV heart failure 
      were excluded. Participants were followed for up to 18 months, regardless of 
      discontinuation or subsequent AAD switches. Atrial fibrillation recurrence was 
      captured by hospitalization, emergency room visit, or electrocardiogram-based 
      documentation of AF. Confounding bias was controlled for in the analysis of AF 
      recurrence using multivariate models of 19 variables for adjustment. A total of 
      1009 participants [mean age 67.2 (10.8) years, male to female ratio 1.3] were 
      recruited from 170 centres, 693 (69%) of which were from across Europe and the 
      remaining 316 (31%) from the USA. At the time of enrolment, participants were 
      taking dronedarone (51%) or other AADs (49%) [flecainide or propafenone (42%), 
      sotalol (11%), and amiodarone (47%)]. No significant differences in the risk of 
      first confirmed AF recurrence with dronedarone vs. other AADs [crude hazard ratio 
      (HR) 1.10 (95% confidence interval 0.85-1.42); adjusted HR 1.16 (0.87-1.55)] were 
      found, irrespective of whether univariate or multivariate models were used. 
      Reported safety events were in accordance with the known safety profile of 
      dronedarone. CONCLUSION: In this population of patients from either Europe or the 
      USA receiving dronedarone or another AAD, the effectiveness of dronedarone was 
      comparable to that observed for other AADs in preventing first AF recurrence.
CI  - (c) The Author(s) 2021. Published by Oxford University Press on behalf of the 
      European Society of Cardiology.
FAU - Khachatryan, Artak
AU  - Khachatryan A
AUID- ORCID: 0000-0003-3888-2347
AD  - (Pharmaco)*Epidemiologist with Laser Group at Time of the Study, London, UK.
FAU - Merino, Jose L
AU  - Merino JL
AUID- ORCID: 0000-0002-1737-1903
AD  - University Hospital La Paz, Autonoma University, Arrhythmia & Robotic EP Unit, 
      IdiPaz, Madrid, Spain.
FAU - de Abajo, Francisco Jose
AU  - de Abajo FJ
AUID- ORCID: 0000-0001-9119-8646
AD  - Department of Biomedical Sciences, University Hospital Principe de Asturias, 
      Clinical Pharmacology Unit, University of Alcala (IRYCIS), Alcala de Henares, 
      Madrid, Spain.
FAU - Botto, Giovanni L
AU  - Botto GL
AUID- ORCID: 0000-0002-8049-7517
AD  - ASST Rhodense, Rho & Garbagnate Hospitals, Head of Electrophysiology and Clinical 
      Arrhythmology, Milan, Italy.
FAU - Kirchhof, Paulus
AU  - Kirchhof P
AUID- ORCID: 0000-0002-1881-0197
AD  - Department of Cardiology, University Heart and Vascular Centre UKE, Hamburg, 
      Germany.
AD  - German Centre for Cardiovascular Research (DZHK), Partner Site 
      Hamburg/Kiel/Lubeck, Hamburg, Germany.
AD  - University of Birmingham, Institute of Cardiovascular Sciences, Birmingham, UK.
FAU - Breithardt, Guenter
AU  - Breithardt G
AD  - Department of Cardiovascular Medicine, University Hospital of Munster, Munster, 
      Germany.
FAU - Stambler, Bruce
AU  - Stambler B
AUID- ORCID: 0000-0001-5692-2619
AD  - Piedmont Heart Institute, Atlanta, GA, USA.
FAU - Abenhaim, Lucien
AU  - Abenhaim L
AUID- ORCID: 0000-0001-6106-9923
AD  - Center for Risk Research CRRx Inc, Montreal, Canada.
AD  - London School of Hygiene & Tropical Medicine, London, UK.
FAU - Grimaldi-Bensouda, Lamiae
AU  - Grimaldi-Bensouda L
AUID- ORCID: 0000-0003-1952-5467
AD  - Hospital Group Paris-Saclay, Assistance Publique- Hopitaux de Paris, Paris, 
      France.
AD  - Paris-Saclay University, INSERM, CESP Anti-Infective Evasion and 
      Pharmacoepidemiology Team, Paris, France.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - England
TA  - Europace
JT  - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal 
      of the working groups on cardiac pacing, arrhythmias, and cardiac cellular 
      electrophysiology of the European Society of Cardiology
JID - 100883649
RN  - 0 (Anti-Arrhythmia Agents)
RN  - JQZ1L091Y2 (Dronedarone)
RN  - N3RQ532IUT (Amiodarone)
SB  - IM
MH  - Aged
MH  - *Amiodarone/adverse effects
MH  - Anti-Arrhythmia Agents/adverse effects
MH  - *Atrial Fibrillation/chemically induced/diagnosis/drug therapy
MH  - Cohort Studies
MH  - Dronedarone/adverse effects
MH  - Female
MH  - Humans
MH  - Male
PMC - PMC9282916
OTO - NOTNLM
OT  - Atrial fibrillation
OT  - Cardiovascular
OT  - Cohort
OT  - Dronedarone
OT  - Effectiveness
OT  - Safety
EDAT- 2021/11/19 06:00
MHDA- 2022/07/19 06:00
PMCR- 2021/11/18
CRDT- 2021/11/18 08:50
PHST- 2021/08/06 00:00 [received]
PHST- 2021/10/26 00:00 [accepted]
PHST- 2021/11/19 06:00 [pubmed]
PHST- 2022/07/19 06:00 [medline]
PHST- 2021/11/18 08:50 [entrez]
PHST- 2021/11/18 00:00 [pmc-release]
AID - 6430919 [pii]
AID - euab262 [pii]
AID - 10.1093/europace/euab262 [doi]
PST - ppublish
SO  - Europace. 2022 Jul 15;24(6):899-909. doi: 10.1093/europace/euab262.